ASND Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 -0.14%, SMA50 3.92%, SMA200 15.14%). The stock’s 14-day RSI is 53.48 (neutral), while the ATR of 10.13 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -7.68% below its high and over 80.08% above its low. Average 10-day trading volume of 820.59 thousand shares is slightly above the 3-month average of 686.86 thousand, indicating heightened recent market interest.

Ascendis Pharma A/S (NASDAQ:ASND) closed at $230.21 USD, gaining $3.38 (1.49%) from the previous close of $226.83. The stock is currently within 5% of its 52-week high $124.06 and $242.00. With a market capitalization of about $14.13 billion, Ascendis Pharma A/S is classified as a large-cap and shows lower-than-market volatility (beta ~0.43). Key stats such as the average daily volume over the past year has been around 702.62 thousand shares, volume is running light vs its 52-week average. Headquartered in Hellerup, None, Ascendis Pharma A/S operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jan Moller Mikkelsen, the company employs approximately 1,017 people and listed since January 28, 2015. Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs.

Ascendis Pharma A/S last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$80.97. This means the shares are trading below this model’s fair value.

Ascendis Pharma A/S has 61.38 million shares outstanding. The public float is 60.56 million shares, elevated short interest at 5.69% of float. This equals 2.90 million shares. The short ratio is 4.43 days. Institutional investors hold 106.97% of the float. Insiders own 0.76%.

Ascendis Pharma A/S generated EPS of -$4.20 over the past year. Five-year average earnings growth is 14.76%. The latest quarter delivered EPS of -$1.36. The next quarter is forecast at $0.42. Next year's EPS is expected at $18.33. Analyst sentiment is bullish. Analyst rating data shows there are 20 Strong Buy ratings, 9 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $342.00 to $200.00. The high target offers 48.56% upside. The low target suggests -13.12% downside. The mean target is $258.79. This offers 12.41% upside. Ascendis Pharma A/S earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by 231.36%. The prior quarter beat by -34.51%. Over the last six quarters, Apple has recorded several small beats. These include 33.12% in September 03, 2024.

Ascendis Pharma A/S trades at a P/E ratio of -51.48, slightly below the S&P 500 average, with a price-to-sales ratio of 16.33 and a price-to-book ratio of -72.02 indicating negative book value, which may reflect financial stress. The P/FCF stands at 274.01, also above market averages.

Our AI price prediction model suggests that Ascendis Pharma A/S stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.86%, with price expected at $221.33 by March 04, 2026, within a range of $214.39 to $228.19 3-Month Outlook: Projected rise of 13.42%, reaching $261.10 by May 19, 2026, with a range of $258.18 to $264.36. 1-Year Outlook: Projected gain of 15.64%, with price at $266.21 by February 18, 2027, within a range of $259.96 to $273.76.

Ascendis Pharma A/S (NASDAQ:ASND) shares are flat 1.1% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Ascendis Pharma A/S trading at a premium to the broader market with a P/E of -51.48. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $189.28, suggesting -17.78% downside. Our AI forecast model points to short-term weakness (-3.86% over two weeks), a medium-term rise (13.42% over three months), and a longer-term gain (15.64% over one year), with expected trading ranges indicating moderate volatility.